Manejo del Cáncer de Vejiga sin Invasión Muscular de Alto Riesgo.

Angela B. Smith

doi:10.54212/27068048.v6i1.73

Autores/as

Angela B. Smith

DOI:

https://doi.org/10.54212/27068048.v6i1.73

Palabras clave:

Importancia de la re-resección, Uso juicioso de biomarcadores, BCG es la primera línea

Resumen

El cáncer de vejiga no músculo invasivo es una neoplasia maligna común. Entre todos los pacientes diagnosticados con cáncer de vejiga, el 75 % se presenta como no invasivo y el 70 % recurre después de la resección transuretral del tumor vesical (TURBT), generalmente dentro de los 3 años.1 Desafortunadamente, el 15-20 % progresa a enfermedad muscular invasiva. La progresión es más probable entre los pacientes con factores de riesgo significativos: mayor estadio, grado, mayor tamaño, antecedentes de recurrencia previa y multiplicidad y presencia de carcinoma in situ. Estos factores de riesgo forman la base de las categorías de riesgo de las guías de la American Urological Association, por las cuales se recomienda toda la vigilancia, el diagnóstico y el tratamiento.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.

https://doi.org/10.3322/caac.21332 DOI: https://doi.org/10.3322/caac.21332

Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. The Journal of urology 2016;196:1021-9. https://doi.org/10.1016/j.juro.2016.06.049 DOI: https://doi.org/10.1016/j.juro.2016.06.049

Linder BJ, Boorjian SA, Cheville JC, et al. The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? The Journal of urology 2013;190:1692-6. https://doi.org/10.1016/j.juro.2013.05.040 DOI: https://doi.org/10.1016/j.juro.2013.05.040

Herr HW. Role of Repeat Resection in Non-Muscle-Invasive Bladder Cancer. J Natl Compr Canc Netw 2015;13:1041-6.

https://doi.org/10.6004/jnccn.2015.0123 DOI: https://doi.org/10.6004/jnccn.2015.0123

Lotan Y, Bensalah K, Ruddell T, Shariat SF, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. The Journal of urology 2008;179:2164-9. https://doi.org/10.1016/S0022-5347(08)61800-5

https://doi.org/10.1016/j.juro.2008.01.105 DOI: https://doi.org/10.1016/j.juro.2008.01.105

Savic S, Zlobec I, Thalmann GN, et al. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of non muscle-invasive bladder cancer after intravesical Bacillus Calmette-Guerin therapy. Int J Cancer 2009;124:2899-904.

https://doi.org/10.1002/ijc.24258 DOI: https://doi.org/10.1002/ijc.24258

Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209-16. https://doi.org/10.1046/j.1464-410x.2001.02306.x DOI: https://doi.org/10.1046/j.1464-410x.2001.02306.x

Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. The Journal of urology 2000;163:1124-9.

https://doi.org/10.1016/S0022-5347(05)67707-5 DOI: https://doi.org/10.1016/S0022-5347(05)67707-5

https://doi.org/10.1097/00005392-200004000-00014 DOI: https://doi.org/10.1097/00005392-200004000-00014

Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guerin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. European urology 2013;63:462-72. https://doi.org/10.1016/j.eururo.2012.10.039 DOI: https://doi.org/10.1016/j.eururo.2012.10.039

Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? The Journal of urology 2001;166:1296-9. https://doi.org/10.1016/S0022-5347(05)65756-4 DOI: https://doi.org/10.1016/S0022-5347(05)65756-4

Olsen LH, Genster HG. Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. Scand J Urol Nephrol Suppl 1995;172:33-6.